Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia

• Published in: Cardiovascular diabetology Vol. 22; no. 1; pp. 1 - 11
• Main Authors: tin, Elena, Lundin, Magnus, Mellbin, Linda, Norhammar, Anna, Näsman, Per, Smetana, Stina, Sörensson, Peder, Ferrannini, Ele, Rydén, Lars, Ferrannini, Giulia
• Format: Journal Article
• Language: English
• Published: London BioMed Central 11.08.2023; BMC
• Subjects: Acute coronary syndromes; Adenosine; Angina; Angina pectoris; Beta cells; Blood pressure; Cardiac magnetic resonance; Cardiovascular diseases; Chromium; Contraindications; Diabetes; Diabetes mellitus (non-insulin dependent); Dysglycaemia; Empagliflozin; Glucose; Glucose tolerance; Heart; Heart attacks; Heart failure; Insulin resistance; Magnetic resonance imaging; Mannose; Mass spectrometry; Myocardial infarction; Patients; Peptides; Plasma; Scientific imaging; Ventricle; Sweden
• ISSN: 1475-2840
• DOI: 10.1186/s12933-023-01950-0

BackgroundEmpagliflozin reduces the risk of cardiovascular disease (CVD) in patients with type 2 diabetes (T2DM) and high cardiovascular risk via mechanisms which have not been fully explained. The mechanisms of such benefit have not been fully understood, and whether empagliflozin can be safely administered as first-line treatment in patients with CVD at the initial stages of glycaemic perturbations remains to be established. We investigated the effects of empagliflozin on insulin resistance, insulin sensitivity and β-cell function indexes in patients with a recent acute coronary event and newly detected dysglycaemia, i.e., impaired glucose tolerance (IGT) or T2DM.MethodsForty-two patients (mean age 67.5 years, 19% females) with a recent myocardial infarction (n = 36) or unstable angina (n = 6) and newly detected dysglycaemia were randomized to either empagliflozin 25 mg daily (n = 20) or placebo (n = 22). Patients were investigated with stress-perfusion cardiac magnetic resonance imaging before randomization, 7 months after the start of study drug and 3 months following its cessation. Indexes of insulin resistance, sensitivity and β-cell function were calculated based on glucose and insulin values from 2-hour oral glucose tolerance tests (OGTT) and fasting C-peptide. The differences in glucose, insulin, C-peptide, mannose levels and indexes between the two groups were computed by repeated measures ANOVA including an interaction term between the treatment allocation and the time of visit.ResultsAfter 7 months, empagliflozin significantly decreased glucose and insulin values during the OGTT, whereas C-peptide, mannose and HbA1c did not differ. Empagliflozin significantly improved insulin sensitivity indexes but did not impact insulin resistance and β-cell function. After cessation of the drug, all indexes returned to initial levels. Insulin sensitivity indexes were inversely correlated with left ventricular mass at baseline.ConclusionsEmpagliflozin improved insulin sensitivity indexes in patients with a recent coronary event and drug naïve dysglycaemia. These findings support the safe use of empagliflozin as first-line glucose-lowering treatment in patients at very high cardiovascular risk with newly diagnosed dysglycaemia.Trial registration numberEudraCT number 2015-004571-73.